Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT06475235Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in primary central nervous system lymphoma (PCNSL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Number of Patients Experienced Dose Limiting Toxicity at 28 days. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06475235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475235.